SCHEMBL3881749

SCHEMBL3881749

COC(=O)CCc1cc(Cl)c(OCC2CCCC2)c(-c2ccc3ccccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
FABP4 P15090 3/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
CNR1 P21554 2/20 0.39
SLC6A3 Q01959 3/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
APP P05067 2/20 0.38
REN P00797 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PTPN1 P18031 2/20 0.36
ABL1 P00519 1/20 0.36
MGLL Q99685 1/20 0.36
SSTR3 P32745 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882877 0.89 THRA (0.55) CCNCCDK8FABP4THRATHRB
SCHEMBL3882050 0.89 CCNC (0.46) CCNCCDK8FABP4THRATHRB
SCHEMBL3689404 0.89 THRA (0.53) CCNCCDK8FABP4THRATHRB
SCHEMBL3685120 0.85 THRA (0.40) FABP4THRATHRBCNR1APP
SCHEMBL3884514 0.85 CCNC (0.43) CCNCCDK8FABP4THRATHRB
SCHEMBL3883719 0.85 CCNC (0.48) CCNCCDK8SLC6A3SLC6A2SLC6A4
SCHEMBL3882367 0.82 FABP4 (0.44) FABP4THRATHRBCNR1APP
SCHEMBL3687582 0.79 CCNC (0.44) CCNCCDK8SLC6A3SLC6A2SLC6A4
SCHEMBL3680135 0.79 THRA (0.65) THRATHRBHRH3ALDH1A1
SCHEMBL7737493 0.79 THRB (0.48) FABP4THRATHRBHRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 CCNC 2174/4885CDK8 3600/4885FABP4 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.